DE69638119D1 - Verfahren zur Erhöhung der mageren Fleischmasse mit Fettleibigkeitsprotein (OB) Zusammensetzungen - Google Patents

Verfahren zur Erhöhung der mageren Fleischmasse mit Fettleibigkeitsprotein (OB) Zusammensetzungen

Info

Publication number
DE69638119D1
DE69638119D1 DE69638119T DE69638119T DE69638119D1 DE 69638119 D1 DE69638119 D1 DE 69638119D1 DE 69638119 T DE69638119 T DE 69638119T DE 69638119 T DE69638119 T DE 69638119T DE 69638119 D1 DE69638119 D1 DE 69638119D1
Authority
DE
Germany
Prior art keywords
compositions
lean meat
meat mass
increasing lean
obesity protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69638119T
Other languages
German (de)
English (en)
Inventor
Mary Ann Pelleymounter
Christopher Francis Toombs
Michael Benjamin Mann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DE69638119D1 publication Critical patent/DE69638119D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69638119T 1995-11-22 1996-11-04 Verfahren zur Erhöhung der mageren Fleischmasse mit Fettleibigkeitsprotein (OB) Zusammensetzungen Expired - Lifetime DE69638119D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56173295A 1995-11-22 1995-11-22

Publications (1)

Publication Number Publication Date
DE69638119D1 true DE69638119D1 (de) 2010-03-11

Family

ID=24243198

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69638119T Expired - Lifetime DE69638119D1 (de) 1995-11-22 1996-11-04 Verfahren zur Erhöhung der mageren Fleischmasse mit Fettleibigkeitsprotein (OB) Zusammensetzungen
DE69631544T Expired - Lifetime DE69631544T2 (de) 1995-11-22 1996-11-04 Fettleibigkeitsprotein (ob) zur erhögung der mageren körpermasse

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69631544T Expired - Lifetime DE69631544T2 (de) 1995-11-22 1996-11-04 Fettleibigkeitsprotein (ob) zur erhögung der mageren körpermasse

Country Status (15)

Country Link
EP (3) EP1285664B1 (enExample)
JP (2) JP4173914B2 (enExample)
AT (2) ATE259243T1 (enExample)
AU (3) AU7607496A (enExample)
CA (2) CA2236163A1 (enExample)
DE (2) DE69638119D1 (enExample)
DK (1) DK0866720T3 (enExample)
ES (2) ES2217327T3 (enExample)
IL (2) IL124442A0 (enExample)
MX (1) MX9803992A (enExample)
NZ (3) NZ512083A (enExample)
PT (1) PT866720E (enExample)
SI (1) SI0866720T1 (enExample)
WO (1) WO1997018833A1 (enExample)
ZA (1) ZA969605B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
CA2236163A1 (en) * 1995-11-22 1997-05-29 Amgen Inc. Methods of increasing lean tissue mass using ob protein compositions
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US5831017A (en) * 1996-01-25 1998-11-03 Eli Lilly And Company Obesity protein analog compounds and formulations thereof
EP0917469A1 (en) * 1996-04-19 1999-05-26 ZymoGenetics, Inc. Methods for inducing bone formation
WO1998028414A1 (en) * 1996-12-20 1998-07-02 Eli Lilly And Company Anti-obesity proteins
EP1835030A1 (en) * 1996-12-20 2007-09-19 Amgen, Inc. OB fusion protein compositions and methods
US20020019352A1 (en) * 1997-04-17 2002-02-14 David N. Brems Stable, active, human ob protein compositions and methods
EP0950417A3 (en) 1998-02-23 2000-02-23 Pfizer Products Inc. Treatment of skeletal disorders
WO1999053939A1 (en) * 1998-04-20 1999-10-28 Mayo Foundation For Medical Education And Research Treatment of osteoporosis with leptin
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
AU1134000A (en) * 1998-10-27 2000-05-15 Eli Lilly And Company Prevention of muscle mass loss with leptin receptor ligands
EP1151102B1 (en) * 1999-02-12 2006-04-19 Amgen Inc. Glycosylated leptin compositions and related methods
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
ATE475094T1 (de) 2001-10-22 2010-08-15 Amgen Inc Verwendung von leptin zur behandlung von lipoatrophie im menschen und verfahren zur bestimmmung einer prädisposition gegenüber der behandlung
ATE486842T1 (de) 2002-03-12 2010-11-15 Merck Sharp & Dohme Substituierte amide
JP2008505119A (ja) * 2004-06-30 2008-02-21 ネクター セラピューティクス アラバマ，コーポレイション 高分子−第ｉｘ因子部分の抱合体
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
DK1814590T4 (da) 2004-11-01 2014-02-24 Amylin Pharmaceuticals Llc Behandling af obesitet og beslægtede sygdomme.
WO2008048691A2 (en) * 2006-10-18 2008-04-24 Amylin Pharmaceuticals, Inc. Use of leptin for treating post-lipectomy ectopic fat deposition and other post-lipectomy associated disorders
WO2009149379A2 (en) 2008-06-05 2009-12-10 Regents Of The University Of Michigan Use of leptin for the treatment of fatty liver diseases and conditions
MX349054B (es) 2010-09-28 2017-07-07 Aegerion Pharmaceuticals Inc Leptinas altamente solubles.
CN111529535A (zh) 2012-09-27 2020-08-14 儿童医学中心公司 用于治疗肥胖症的化合物和其使用方法
PT3074033T (pt) 2013-11-26 2019-02-08 Childrens Medical Ct Corp Compostos para o tratamento de obesidade e métodos de utilização dos mesmos
US20170209408A1 (en) 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
DK3509624T3 (da) 2016-09-12 2023-11-13 Amryt Pharmaceuticals Inc Fremgangsmåder til detektering af anti-leptin-neutraliserende antistoffer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1228925B (it) * 1987-08-07 1991-07-10 Eniricerche Spa Procedimento per la preparazione dell'ormone della crescita umano
DK173142B1 (da) * 1988-08-24 2000-02-07 Natinco Nv Fremgangsmåde til forbedring af kødkvaliteten og foderomsætningseffektiviteten for grise
US5028440A (en) * 1990-01-30 1991-07-02 Iowa State University Research Foundation, Inc. Method of raising meat producing animals to increase lean tissue development
DE4428146A1 (de) * 1993-08-13 1995-02-16 Putzmeister Maschf Verfahren und Anordnung zur Oberflächenbearbeitung von Großobjekten
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
CA2236163A1 (en) * 1995-11-22 1997-05-29 Amgen Inc. Methods of increasing lean tissue mass using ob protein compositions
IL124831A0 (en) * 1995-12-27 1999-01-26 Genentech Inc Ob protein derivatives having prolonged half-life
EP1835030A1 (en) * 1996-12-20 2007-09-19 Amgen, Inc. OB fusion protein compositions and methods
IL132380A0 (en) * 1997-04-17 2001-03-19 Amgen Inc Compositions comprising conjugates of stable active human ob protein with antibody fc chain and methods

Also Published As

Publication number Publication date
CA2236163A1 (en) 1997-05-29
EP0866720A1 (en) 1998-09-30
EP1285664A2 (en) 2003-02-26
NZ512083A (en) 2003-02-28
AU763755B2 (en) 2003-07-31
WO1997018833A1 (en) 1997-05-29
JP2002206000A (ja) 2002-07-23
EP0956862A1 (en) 1999-11-17
AU4265200A (en) 2000-09-21
EP1285664A3 (en) 2003-07-30
AU763769B2 (en) 2003-07-31
NZ511617A (en) 2003-08-29
MX9803992A (es) 1998-09-30
JP4173914B2 (ja) 2008-10-29
IL124442A0 (en) 1998-12-06
EP1285664B1 (en) 2010-01-20
CA2358862A1 (en) 1997-05-29
JP4227325B2 (ja) 2009-02-18
EP0866720B1 (en) 2004-02-11
JP2000500492A (ja) 2000-01-18
AU4265300A (en) 2000-09-07
PT866720E (pt) 2004-06-30
ES2339846T3 (es) 2010-05-26
IL127926A0 (en) 1999-11-30
ATE259243T1 (de) 2004-02-15
AU7607496A (en) 1997-06-11
IL127926A (en) 2006-08-20
DK0866720T3 (da) 2004-06-14
SI0866720T1 (en) 2004-10-31
DE69631544D1 (de) 2004-03-18
NZ527007A (en) 2005-01-28
DE69631544T2 (de) 2004-12-23
ZA969605B (en) 1997-06-02
ES2217327T3 (es) 2004-11-01
ATE455554T1 (de) 2010-02-15

Similar Documents

Publication Publication Date Title
ATE455554T1 (de) Verfahren zur erhöhung der mageren fleischmasse mit fettleibigkeitsprotein (ob) zusammensetzungen
DE69022163D1 (de) Steriles erzeugnis und verfahren zur sterilisierung und zusammenbau dieses erzeugnisses.
NO970155L (no) Kunstig ekstracellulær biologisk matrise samt fremgangsmåte ved fremstilling derav
DE60137430D1 (de) Gewebeimplant zur wiederherstellung von knorpelgewebe
AU1371995A (en) Method and apparatus for securing soft tissues, tendons and ligaments to bone
DE3750342D1 (de) Menschliches gamma-interferon-spezifisches Rezeptorprotein, Antikörper gegen dieses Protein, Verfahren zur Herstellung dieses Proteins und dieses Antikörpers und dieses Protein und diesen Antikörper enthaltende Zusammensetzungen.
DE69535274D1 (de) Verwendung eines menschlichen interleukin-11 rezeptors
HUP9901688A3 (en) Novel peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits
ATE167232T1 (de) Protein mit knochenbildungs-eigenschaften und verfahren zu seiner herstellung
ATE122467T1 (de) Verfahren zur detektion von knochen- und anderen bindegewebeerkrankungen bei menschen und tieren.
GR3018371T3 (en) Method for identifying or determining proteins and applications therefor.
ATE181549T1 (de) Verfahren zur herstellung von (s)-3-amino-1- substituiert-pirrolidine
DE69734464D1 (de) Verfahren zur expression und herstellung von rekombinantem, menschlichem beta-cis-interferon
ATE432287T1 (de) Peptidfragmente mit den zelltod verhindernder aktivität
EP0909172A4 (en) METHODS AND COMPOSITIONS FOR TREATING URINARY INCONTINENCE WITH ENANTIOMERIC ENRICHED (R, s) -GLYCOPYRROLATE
ATE128872T1 (de) Gesteigerte erzeugung von proteinen in tieren.
SE9803962D0 (sv) Nucleic acid encoding a nervous tissue sodium channel
ATE407944T1 (de) Mit trp-proteinen verwandtes protein mtr1 und dieses codierende dna-sequenz
AU7377296A (en) Method for treating hepatitis virus infection
DE68916485D1 (de) Verfahren und Vorrichtung zur schnellen Fixierung von Geweben.
MD899G2 (ro) Procedeu de activizare a osteogenezei reparatorii
DE60128026D1 (de) Verfahren zur Beurteilung der Widerstandsfähigkeit gegen den Ausbruch von Leukämie bei Rindern

Legal Events

Date Code Title Description
8364 No opposition during term of opposition